Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Siena – page 18

225 clinical trials in Siena, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Siena at a glance
225
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

225 trials in Siena

Open in trial search

Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MBS2320
  • Sponsor:Modern Biosciences Limited

Malignant melanoma

Not recruiting

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of BMS-986449 and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986449-03
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DCC-3116
  • Sponsor:Deciphera Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Olaparib for Patients with Advanced Cancer Having HRRm or HRD Mutations

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Merck Sharp & Dohme LLC

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Siena

What the registry says about research in the country

01 Respiratory Research

Clinical investigations focusing on pulmonary conditions, including studies of treatments for idiopathic pulmonary fibrosis and chronic rhinosinusitis. Research also includes innovative approaches for respiratory syncytial virus prevention in older adults.

  • Pulmonary Fibrosis Treatment Studies
  • Chronic Rhinosinusitis Management
  • RSV Vaccine Development
02 Oncology Studies

Comprehensive research into various cancer types, with emphasis on advanced therapies for lung cancer, Merkel cell carcinoma, and hematological malignancies.

  • Non-Small Cell Lung Cancer Treatments
  • Leukemia Therapies
  • Novel Cancer Immunotherapies
03 Metabolic & Cardiovascular Research

Innovative trials examining treatments for heart failure prevention and obesity management, with focus on new therapeutic combinations and cardiovascular safety assessments.

  • Heart Failure Prevention
  • Obesity Management
  • Cardiovascular Risk Reduction
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.